Trade-Ideas LLC identified

Neurocrine Biosciences

(

NBIX

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Neurocrine Biosciences as such a stock due to the following factors:

  • NBIX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $52.8 million.
  • NBIX has traded 153,621 shares today.
  • NBIX is trading at 2.83 times the normal volume for the stock at this time of day.
  • NBIX is trading at a new high 6.06% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in NBIX with the Ticky from Trade-Ideas. See the FREE profile for NBIX NOW at Trade-Ideas

More details on NBIX:

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 8 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Neurocrine Biosciences has been 806,000 shares per day over the past 30 days. Neurocrine has a market cap of $3.5 billion and is part of the health care sector and drugs industry. The stock has a beta of -1.10 and a short float of 9% with 4.07 days to cover. Shares are up 60.2% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Neurocrine Biosciences as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and feeble growth in the company's earnings per share.

Highlights from the ratings report include:

  • Compared to its closing price of one year ago, NBIX's share price has jumped by 188.41%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
  • NBIX has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign.
  • The gross profit margin for NEUROCRINE BIOSCIENCES INC is currently extremely low, coming in at 0.00%. NBIX has continued with the weak profit margin when compared to the same quarter of last year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 79.3% when compared to the same quarter one year ago, falling from -$13.38 million to -$23.99 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.